Hysteroscopy pp 291-299 | Cite as

Tamoxifen: An Update

  • Jesus S. Jimenez
  • Alvaro Diez
  • Alejandro Olloqui
Chapter

Abstract

Tamoxifen is a selective estrogen receptor modulator (SERM). These agents act as competitive inhibitors of estrogens, binding to estrogen receptors (ERs) and, depending on the tissue of action, having an agonist or antagonist effect on these receptors. The mechanism of action and main effects of tamoxifen on endometrium will be reviewed in this chapter. Tamoxifen has shown to slightly increase the risk of atypical endometrial lesions, which can be diagnosed with hysteroscopy. An optimal baseline evaluation and follow-up of patients treated with tamoxifen, in order to diagnose and treat these lesions has not been established.

Keywords

Tamoxifen Endometrial changes Hysteroscopy findings 

References

  1. 1.
    Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 2003;9:1980.PubMedGoogle Scholar
  2. 2.
    Beato M, Sánchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev. 1996;17:587.CrossRefPubMedGoogle Scholar
  3. 3.
    Riggs BL, Hartmann LC. Selective estrogen-receptor modulators—mechanisms of action and application to clinical practice. N Engl J Med. 2003;348:618–29.CrossRefPubMedGoogle Scholar
  4. 4.
    Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996;392:49.CrossRefPubMedGoogle Scholar
  5. 5.
    Speirs V, Carder PJ, Lane S, et al. Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol. 2004;5:174.CrossRefPubMedGoogle Scholar
  6. 6.
    Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology. 1999;140:5566.CrossRefPubMedGoogle Scholar
  7. 7.
    Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell. 2004;5:207.CrossRefPubMedGoogle Scholar
  8. 8.
    MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 1998;50:151.PubMedGoogle Scholar
  9. 9.
    Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609–18.CrossRefPubMedGoogle Scholar
  10. 10.
    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–67.CrossRefGoogle Scholar
  11. 11.
    Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18:937.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23:279–302.CrossRefPubMedGoogle Scholar
  13. 13.
    Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.CrossRefGoogle Scholar
  14. 14.
    Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab. 1995;80:3191.PubMedGoogle Scholar
  15. 15.
    Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and b. Endocrinology. 1997;138:863–70.CrossRefPubMedGoogle Scholar
  16. 16.
    Gustafsson JA. Estrogen receptor b—a new dimension in estrogen mechanism of action. J Endocrinol. 1999;163:379–83.CrossRefPubMedGoogle Scholar
  17. 17.
    Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County study. JAMA. 2002;288:2123–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Colleoni M, Gelber S, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group trial 13–93. J Clin Oncol. 2006;24:1332–41.CrossRefPubMedGoogle Scholar
  19. 19.
    Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRefGoogle Scholar
  20. 20.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771.CrossRefGoogle Scholar
  21. 21.
    Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev. 2012;10:CD007847.PubMedGoogle Scholar
  22. 22.
    Eggemann H, Ignatov A, Smith BJ, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2013;137:465–70.CrossRefPubMedGoogle Scholar
  23. 23.
    Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28:2114–22.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    von Minckwitz G, Untch M, Nüesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 2011;125:145–56.CrossRefGoogle Scholar
  25. 25.
    Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative ‘Arimidex’ compared to tamoxifen (PROACT) trial. Cancer. 2006;106:2095–103.CrossRefPubMedGoogle Scholar
  26. 26.
    Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108–16.CrossRefPubMedGoogle Scholar
  27. 27.
    Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol. 1991;9:1283.CrossRefPubMedGoogle Scholar
  28. 28.
    Sawka CA, Pritchard KI, Shelley W, et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. Breast Cancer Res Treat. 1997;44:211.CrossRefPubMedGoogle Scholar
  29. 29.
    Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001;19:343.CrossRefPubMedGoogle Scholar
  30. 30.
    Nelson HD, Smith ME, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:604.CrossRefPubMedGoogle Scholar
  31. 31.
    Day R. Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project. Ann N Y Acad Sci. 2001;949:143.CrossRefPubMedGoogle Scholar
  32. 32.
    Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296–300.CrossRefPubMedGoogle Scholar
  33. 33.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–62.CrossRefPubMedGoogle Scholar
  34. 34.
    Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Garber JE, Halabi S, Tolaney SM, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst. 2010;102:942.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Abramson N, Constantino JP, Garber JE, et al. Effect of Factor V Leiden and prothrombin G20210–>A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst. 2006;98(13):904–10.CrossRefPubMedGoogle Scholar
  37. 37.
    Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817.CrossRefPubMedGoogle Scholar
  38. 38.
    Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst. 2004;96:70.CrossRefPubMedGoogle Scholar
  39. 39.
    Reis SE, Costantino JP, Wickerham DL, et al. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst. 2001;93:16.CrossRefPubMedGoogle Scholar
  40. 40.
    Perez-Medina T, et al. Hysteroscopic dynamic assessment of the endometrium in patients treated with long-term tamoxifen. J Minim Invasive Gynecol. 2011;18(3):349.CrossRefPubMedGoogle Scholar
  41. 41.
    Lahti E, Blanco G, Kauppila A, Apaia-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cáncer patients receiving tamoxifen. Obstet Gynecol. 1993;81:660–4.PubMedGoogle Scholar
  42. 42.
    Berliere M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol. 1998;91:40–4.CrossRefPubMedGoogle Scholar
  43. 43.
    Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF. Second cancers after adjuvant therapy for breast cancer. J Natl Cancer Inst. 1996;88:332–4.Google Scholar
  44. 44.
    Garuty G, Grossi F, Centinaio G, Sita G, Nalli G, Luerti M. Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer. Eur J Obstet Gynecol Reprod Biol. 2007;132:101–6.CrossRefGoogle Scholar
  45. 45.
    Saccardi C, et al. Endometrial surveillance in tamoxifen users: role, timing, and accuracy of hysteroscopic investigation: observational longitudinal cohort study. Endocr Relat Cancer. 2013;20:455–62.CrossRefPubMedGoogle Scholar
  46. 46.
    Ceci O, Bettocchi S, Nappi L, Di Venere R, Pansini MV, Di Fazio F. Comparison of hysteroscopic and hysterectomy findings to assess the diagnostic accuracy of office hysteroscopy in tamoxifen-treated patients with breast cancer. J AAGL. 2003;10:392–5.Google Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Jesus S. Jimenez
    • 1
  • Alvaro Diez
    • 1
  • Alejandro Olloqui
    • 1
  1. 1.Diagnostic—Surgical Hysteroscopy Unit, Obstetrics and Gynecology Service, Hospital 12 October, School of MedicineComplutense UniversityMadridSpain

Personalised recommendations